Final approval has been granted for a drug that treats a rare genetic condition that leads to joint pain and in some cases death.
Nitisinone has been approved for use after trials showed it can halt the progress of Alkaptonuria (AKU) and provide hope for a pain free future.
Julien Sireau was diagnosed with AKU 20 years ago and his family has dedicated his life to campaigning and fundraising to help find a cure.
SUBSCRIBE to our YouTube channel for more videos: http://www.youtube.com/skynews
Follow us on Twitter: https://twitter.com/skynews
Like us on Facebook: https://www.facebook.com/skynews
Follow us on Instagram: https://www.instagram.com/skynews
For more content go to http://news.sky.com and download our apps:
Apple: https://itunes.apple.com/gb/app/sky-news/id316391924?mt=8
Android https://play.google.com/store/apps/details?id=com.bskyb.skynews.android&hl=en_GB
Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí: https://www.youtube.com/skynewsespanol
Nitisinone has been approved for use after trials showed it can halt the progress of Alkaptonuria (AKU) and provide hope for a pain free future.
Julien Sireau was diagnosed with AKU 20 years ago and his family has dedicated his life to campaigning and fundraising to help find a cure.
SUBSCRIBE to our YouTube channel for more videos: http://www.youtube.com/skynews
Follow us on Twitter: https://twitter.com/skynews
Like us on Facebook: https://www.facebook.com/skynews
Follow us on Instagram: https://www.instagram.com/skynews
For more content go to http://news.sky.com and download our apps:
Apple: https://itunes.apple.com/gb/app/sky-news/id316391924?mt=8
Android https://play.google.com/store/apps/details?id=com.bskyb.skynews.android&hl=en_GB
Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí: https://www.youtube.com/skynewsespanol
- Category
- World
- Tags
- Sky, Medicines and Healthcare products Regulatory Agenc, NEWS
Sign in or sign up to post comments.
Be the first to comment